Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen Stock Slides 8.3 Percent on Revenue Investigation, Delayed Q3 Earnings

NEW YORK, Nov. 7 (GenomeWeb News) - Shares in Ciphergen Biosystems were down 8.3 percent, or $.16, at $1.77 in mid-afternoon trading after the company said an audit committee has begun investigating $500,000 in sales recorded in the second quarter.


As GenomeWeb News reported earlier today, the company will delay releasing its financial results for the third quarter while the investigation is pending.


Ciphergen is expected to file a late notice with the Securities and Exchange Commission for its quarterly report.

The Scan

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.

EHR Quality Improvement Study Detects Demographic-Related Deficiencies in Cancer Family History Data

In a retrospective analysis in JAMA Network Open, researchers find that sex, ethnicity, language, and other features coincide with the quality of cancer family history information in a patient's record.

Inflammatory Bowel Disease Linked to Gut Microbiome Community Structure Gradient in Meta-Analysis

Bringing together data from prior studies, researchers in Genome Biology track down microbial taxa and a population structure gradient with ties to ulcerative colitis or Crohn's disease.

Ancient Greek Army Ancestry Highlights Mercenary Role in Historical Migrations

By profiling genomic patterns in 5th century samples from in and around Himera, researchers saw diverse ancestry in Greek army representatives in the region, as they report in PNAS.